Healthcare entity
medical-devices is the sole category represented across all 1 tracked stories. Integra LifeSciences is most often covered alongside Acclarent, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 4.7 for the same window.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
medical-devices is the sole category represented across all 1 tracked stories. Integra LifeSciences is most often covered alongside Acclarent, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 4.7 for the same window. At 5, the average consequence score sits below the same-window beat average of 5.6. Integra LifeSciences appears in 1 tracked Healthcare story from February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Integra LifeSciences. Shared-story counts are live from our verified record — not editorial picks.
Integra LifeSciences reported Q4 2025 results that failed to meet investor expectations, driven by persistent manufacturing challenges and a slower-than-anticipated recovery in its Tissue Technologies segment. Despite growth in the newly acquired Acclarent business, the company's conservative 2026 guidance has triggered a significant market sell-off.
Source: finance.yahoo.com · fool.com
Integra LifeSciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
